Abstract
Asthma is a chronic inflammatory disease of the airways and lung mucosa with a strong correlation to atopy and acquired (IgE) immunity1. However, many features of bronchial asthma, such as smooth muscle contraction, mucus secretion and recruitment of inflammatory cells, are consistent with the actions of complement anaphylatoxins, in particular C3a and C5a2. Complement activation forms a central core of innate immune defence against mucosal bacteria, viruses, fungi, helminths and other pathogens. As a system of ‘pattern-recognition molecules’, foreign surface antigens and immune complexes lead to a proteolytic cascade culminating in a lytic membrane attack2,3. The anaphylatoxins C3a and C5a are liberated as activation byproducts and are potent pro-inflammatory mediators that bind to specific cell surface receptors and cause leukocyte activation, smooth muscle contraction and vascular permeability2. Here we show that in a murine model of allergic airway disease, genetic deletion of the C3a receptor protects against the changes in lung physiology seen after allergen challenge. Furthermore, human asthmatics develop significant levels of ligand C3a following intra-pulmonary deposition of allergen, but not saline. We propose that, in addition to acquired immune responses, the innate immune system and complement (C3a in particular) are involved in the pathogenesis of asthma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Burrows, B., Martinez, F. D., Halonen, M., Barbee, R. A. & Cline, M. G. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N. Engl. J. Med. 320, 271–277 ( 1989).
Gerard, N. P. in Asthma (eds Barnes, P. J., Grunstein, M. M., Leff, A. R. & Woolcock, A. J.) 639–651 (Lippincott-Raven, Philadelphia, 1997).
Medzhitov, R. & Janeway, C. A. Jr. Innate immunity: The virtues of a nonclonal system of recognition. Cell 91, 295–298 (1997).
Höpken, U. E., Lu, B., Gerard, N. P. & Gerard, C. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 383, 86–89 (1996).
Höpken, U. E., Lu, B., Gerard, N. P. & Gerard, C. Impaired inflammatory responses in the reverse Arthus Reaction through genetic deletion of the C5a receptor. J. Exp. Med. 186, 749– 756 (1997).
Osaka, H. et al. Expression of C5a receptor in mouse brain: role in signal transduction and neurodegeneration. Neuroscience 88, 1073–1082 (1999).
Bhatia, M. Complement factor C5a exerts an anti-inflammatory effect in acute pancreatitis and pancreatitis-associated lung injury. Am. J. Physiol. (submitted).
Tornetta, M. A., Foley, J. J., Sarau, H. M. & Ames, R. S. The mouse anaphylatoxin C3a receptor. J. Immunol. 158 , 5277–5282 (1997).
Hsu, M. H. et al. Cloning and functional characterization of the mouse C3a anaphylatoxin receptor gene. Immunogenetics 47, 64– 72 (1997).
Chao, T. H. et al. Role of the second extracellular loop of human C3a receptor in agonist binding and receptor function. J. Biol. Chem. 274, 9721–9728 (1999).
Fischer, W. H. et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J. Immunol. 157, 549–556 (1996).
Daffern, P. J. et al. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J. Exp. Med. 181, 2119–2127 (1995).
Nilsson, G. et al. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J. Immunol. 157, 1693– 1698 (1996).
Stimler-Gerard, N. P. & Galli, S. J. Mast cells in anaphylatoxin-induced spasmogenic activity. J. Immunol. 138, 1908–1913 (1987).
Stimler, N. P., Gerard, C. & O'Flaherty, J. T. in Platelet Activating Factor (eds Benveniste, J & Arnoux, B.) 195–203 (Elsevier, Amsterdam, 1983).
Hamelmann, E. et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am. J. Respir. Crit. Care Med. 156, 766–775 ( 1992).
Martin, T. R., Gerard, N. P., Galli, S. J. & Drazen, J. M. Pulmonary responses to bronchoconstrictor agonists in the mouse. J. Appl. Physiol. 64, 2318–2323 (1988).
Smith, J. K., Chi, D. S., Krish, G., Reynolds, S. & Cambron, G. Effect of exercise on complement activity. Ann. Allergy 65, 304–310 (1990).
Onodera, H. et al. Complement system in status asthmatics: analysis of anti-complementary effects induced by methylprendisolone. Arerugi 41, 1567–1574 (1997).
Pepys, J. & Hutchcroft, B. J. Bronchial provocation tests in etiologic diagnosis and analysis of asthma. Am. J. Respir. Crit. Care Med. 112, 829–859 ( 1975).
Bradley, B. L. et al. Eosinophils, T-lymphocytes, mast cells, neutrophils and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J. Allergy Clin. Immunol. 88, 661–674 (1991).
Drazen, J. M. Asthma therapy with agents preventing leukotriene synthesis or action. Proc. Assoc. Am. Physicians 111, 547– 559 (1999).
Barnes, P. J. & Belvisi, M. G. in Asthma (eds Barnes, P. J., Grunstein, M. M., Leff, A. R. & Woolcock, A. J.) 1051– 1063 (Lippincott–Raven, Philadelphia, 1997).
Mattoli, S., Soloperto, M., Marini, M. & Fasoli, A. Levels of endothelin in the bronchoalveolar lavage fluid of patients with symptomatic asthma and reversible airflow obstruction. J. Allergy Clin. Immunol. 88, 376–384 (1991).
Schwartz, L. B. et al. Generation of C3a anaphylatoxin from human C3 by mast cell tryptase. J. Immunol. 130, 1891– 1895 (1983).
Humbles, A. A. et al. Kinetics of eotaxin generation and its relationship to eosinophil accumulation in allergic airways disease: analysis in a guinea pig model in vivo. J. Exp. Med. 186, 601– 612 (1997).
American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am. Rev. Respir. Dis. 144, 1202–1218 (1991).
Acknowledgements
We thank T. Martin and J. Drazen for comments and advice; J. Brewer for assistance; D. Zurakowski for help and advice with analysing the statistics; and the staff of ARCH at Children's Hospital for animal care. This work was supported in part by grants from the NIH to N.P.G. and C.G. at the Perlmutter laboratory and Pfizer Central Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Humbles, A., Lu, B., Nilsson, C. et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma . Nature 406, 998–1001 (2000). https://doi.org/10.1038/35023175
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/35023175
This article is cited by
-
The complement cascade in lung injury and disease
Respiratory Research (2024)
-
Complement therapeutics are coming of age in rheumatology
Nature Reviews Rheumatology (2023)
-
Lung mesenchymal stromal cells influenced by Th2 cytokines mobilize neutrophils and facilitate metastasis by producing complement C3
Nature Communications (2021)
-
Complement peptide C3a receptor 1 promotes optic nerve degeneration in DBA/2J mice
Journal of Neuroinflammation (2020)
-
C3a is required for ILC2 function in allergic airway inflammation
Mucosal Immunology (2018)